1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2007
-
Mark
Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up
(
- Contribution to journal › Article
- 2004
-
Mark
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.
(
- Contribution to journal › Article
-
Mark
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study.
(
- Contribution to journal › Article
- 2003
-
Mark
CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial
(
- Contribution to journal › Article
- 2001
-
Mark
Expression of the B-cell transcription factor PU.1 is strongly correlated with CD10, CD79a, CD20, CD22, and bcl-6 expression in diffuse large B-cell lymphoma (DLBCL)
(
- Contribution to journal › Article
-
Mark
Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial
(
- Contribution to journal › Article
- 1999
-
Mark
CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial
(
- Contribution to journal › Article